During the Walgreens Boots Alliance’s conference call this week on its third-quarter results, co-COO Alex Gourlay told analysts that WBA will address Valeant Pharmaceuticals International’s concerns about its distribution arrangement with the company. Under the deal, announced in December, WBA and Valeant entered agreements in which the drug maker will directly distribute branded prescription drugs
NEW YORK — Joseph Papa has resigned as chairman and chief executive officer of Perrigo Co. plc to join Valeant Pharmaceuticals International Inc. as chairman and CEO. Valeant said Monday that Papa, 60, is slated to start at the company by early May. Papa will succeed J. Michael Pearson, who is expected to remain as
LAVAL, Quebec — J. Michael Pearson is slated to step down as chief executive officer of Valeant Pharmaceuticals International Inc., which has begun a search for a new CEO. The embattled drug maker said Monday that its board has initiated a search to identify a candidate to take over for Pearson, who will continue to
LAVAL, Quebec — Valeant Pharmaceuticals International Inc. has named former chief financial officer Howard Schiller as interim chief executive officer, effective immediately. Valeant said Wednesday that it appointed Schiller to the interim role because chairman and CEO J. Michael Pearson remains in the hospital, where he is being treated for severe pneumonia, and the timing
DEERFIELD, Ill. — Walgreens and Valeant Pharmaceuticals International Inc. have inked a distribution deal that will cut prices of Valeant prescription products at Walgreens by 10%, and may be extended to independent retail pharmacies. The discount will apply to wholesale list prices and will be phased in over the next six to nine months. The
LAVAL, Quebec, and DEERFIELD, Ill. — Valeant Pharmaceuticals International Inc. and Walgreens have entered agreements in which the drug maker will directly distribute branded prescription drugs in a range of therapeutical areas to the pharmacy chain at reduced pricing. Valeant said Monday that, under the fulfillment agreement, it will cut the wholesale list prices of
LAVAL, Quebec — Valeant Pharmaceuticals International Inc. plans to acquire Sprout Pharmaceuticals Inc., the maker of a just-approved drug for sexual desire disorder in women, for about $1 billion in cash. Valeant said Thursday that it expects to close the deal in the third quarter of this year, pending customary closing conditions and regulatory approval.
LAVAL, Quebec, and RALEIGH, N.C. — Valeant Pharmaceuticals International Inc. has hiked its offer to buy Salix Pharmaceuticals, Ltd. under an amended agreement. The companies said Monday that Valeant boosted its cash offer to acquire all the outstanding common stock of Salix to $173 per share, or a total deal of about $15.8 billion, from $158
